Revenue
19.2 thousand Unit_Standard_USD_SXl3_C132kGDPpEJ3t7SyQ
2023 Q1 · Unit_Standard_USD_SXl3_C132kGDPpEJ3t7SyQ
Exact inputs and evidence
- Revenue: 19190 Unit_Standard_USD_SXl3_C132kGDPpEJ3t7SyQ Source
Fundies. English
REGENERX BIOPHARMACEUTICALS INC
EDGAR120 filing records in this dataset, filed from 1995-11-14 to 2023-05-15. Reported financial figures are available; chart coverage varies by period.
Latest quarter
Operating margin
-1,588.91%
2023 Q1 · %
Operating cash flow
-189 thousand Unit_Standard_USD_SXl3_C132kGDPpEJ3t7SyQ
2023 Q1 · Unit_Standard_USD_SXl3_C132kGDPpEJ3t7SyQ
Exact inputs and evidence
- Operating Cash Flow: -189333 Unit_Standard_USD_SXl3_C132kGDPpEJ3t7SyQ Source
- Cash and cash equivalents
- 102 thousand Unit_Standard_USD_SXl3_C132kGDPpEJ3t7SyQ Source
Exact value
101557 Unit_Standard_USD_SXl3_C132kGDPpEJ3t7SyQ
- Long-term debt including current maturities
- Not available
- Shares outstanding
- 144 million Unit_Standard_shares_E_3hEVxU50S3WAX_wvDROg Source
Exact value
143549735 Unit_Standard_shares_E_3hEVxU50S3WAX_wvDROg
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2023-05-15.
Financial data available through: 2022-12-31.
Coverage by financial measure
- Revenue: 2 of 11 periods available· newest 2022-12-31
- Operating income: 2 of 11 periods available· newest 2022-12-31
- Net income: 2 of 11 periods available· newest 2022-12-31
- Operating cash flow: 2 of 11 periods available· newest 2022-12-31
- Capital expenditure: 5 of 11 periods available· newest 2016-12-31
- Total assets: Multiple units; comparison withheld· newest 2022-12-31
- Total liabilities: Multiple units; comparison withheld· newest 2022-12-31
- Current assets: Multiple units; comparison withheld· newest 2022-12-31
- Current liabilities: Multiple units; comparison withheld· newest 2022-12-31
- Cash and cash equivalents: Multiple units; comparison withheld· newest 2022-12-31
- long term debt: No compatible figures in this window
- Shares outstanding: Multiple units; comparison withheld· newest 2022-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Revenue
0%Prior period
Unit_Standard_USD_jkFSuOOO40GksqLv6OFPVQ 76,761
–
Current period
Unit_Standard_USD_jkFSuOOO40GksqLv6OFPVQ 76,761
–
Exact inputs and evidence
76761 − 76761 = 0 Unit_Standard_USD_jkFSuOOO40GksqLv6OFPVQ
76761 Unit_Standard_USD_jkFSuOOO40GksqLv6OFPVQ · 2021-01-01 – 2021-12-31
Inspect prior input Prior source76761 Unit_Standard_USD_jkFSuOOO40GksqLv6OFPVQ · 2022-01-01 – 2022-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Net income
−Unit_Standard_USD_jkFSuOOO40GksqLv6OFPVQ 129,700Prior period
−Unit_Standard_USD_jkFSuOOO40GksqLv6OFPVQ 1.6 million
–
Current period
−Unit_Standard_USD_jkFSuOOO40GksqLv6OFPVQ 1.73 million
–
Exact inputs and evidence
-1727455 − -1597755 = -129700 Unit_Standard_USD_jkFSuOOO40GksqLv6OFPVQ
-1597755 Unit_Standard_USD_jkFSuOOO40GksqLv6OFPVQ · 2021-01-01 – 2021-12-31
Inspect prior input Prior source-1727455 Unit_Standard_USD_jkFSuOOO40GksqLv6OFPVQ · 2022-01-01 – 2022-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+Unit_Standard_USD_jkFSuOOO40GksqLv6OFPVQ 49,578Prior period
−Unit_Standard_USD_jkFSuOOO40GksqLv6OFPVQ 990,296
–
Current period
−Unit_Standard_USD_jkFSuOOO40GksqLv6OFPVQ 940,718
–
Exact inputs and evidence
-940718 − -990296 = 49578 Unit_Standard_USD_jkFSuOOO40GksqLv6OFPVQ
-990296 Unit_Standard_USD_jkFSuOOO40GksqLv6OFPVQ · 2021-01-01 – 2021-12-31
Inspect prior input Prior source-940718 Unit_Standard_USD_jkFSuOOO40GksqLv6OFPVQ · 2022-01-01 – 2022-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
2022 2022-01-01 – 2022-12-31
- Revenue Unit_Standard_USD_jkFSuOOO40GksqLv6OFPVQ 76,761 100% of revenue
- Operating costs Derived Unit_Standard_USD_jkFSuOOO40GksqLv6OFPVQ 1.48 million 1,926% of revenue
- Operating income −Unit_Standard_USD_jkFSuOOO40GksqLv6OFPVQ 1.4 million −1,826% of revenue
- Tax, interest and other Derived Unit_Standard_USD_jkFSuOOO40GksqLv6OFPVQ 325,464 424% of revenue
- Net income −Unit_Standard_USD_jkFSuOOO40GksqLv6OFPVQ 1.73 million −2,250% of revenue
Cash
- Operating cash flow −Unit_Standard_USD_jkFSuOOO40GksqLv6OFPVQ 940,718 −1,226% of revenue
- Capital expenditure Unavailable An input is unavailable.
- Free cash flow Derived Unavailable An input is unavailable.
Share of revenue by period
- Net income
- Tax, interest and other
- Operating costs
- 2021 Operating loss: operating costs were 1,831% of revenue.
- 2022 Operating loss: operating costs were 1,926% of revenue.
Values and sources
| Period | Revenue | Operating costs | Operating income | Tax, interest and other | Net income | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| 2021 2021-01-01 – 2021-12-31 | 76761 | 1405272 Derived | -1328511 | 269244 Derived | -1597755 | Unavailable | Source
|
| 2022 2022-01-01 – 2022-12-31 | 76761 | 1478752 Derived | -1401991 | 325464 Derived | -1727455 | Unavailable | Source
|
Amounts are exact, in Unit_Standard_USD_jkFSuOOO40GksqLv6OFPVQ.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
Unit_Standard_USD_jkFSuOOO40GksqLv6OFPVQ 76.8K 2022
Values and sources
| Period | Series | Value(Unit_Standard_USD_jkFSuOOO40GksqLv6OFPVQ) | Source evidence |
|---|---|---|---|
| 2021 | Revenue | 76761 |
|
| 2022 | Revenue | 76761 |
|
Revenue growth
Change in revenue from the same financial period one year earlier.
0% 2022
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2021 | Year over year | No prior comparable period |
|
| 2022 | Year over year | 0% |
|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Operating margin -1,826.4% 2022
Net margin -2,250.4% 2022
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2021 | Operating margin | -1,730.7% |
|
| 2022 | Operating margin | -1,826.4% |
|
| 2021 | Net margin | -2,081.5% |
|
| 2022 | Net margin | -2,250.4% |
|
| 2021 | Free cash flow margin | Not reported |
|
| 2022 | Free cash flow margin | Not reported |
|
Operating cash flow
Cash generated by the company’s normal business operations.
Unit_Standard_USD_jkFSuOOO40GksqLv6OFPVQ -940.7K 2022
Values and sources
| Period | Series | Value(Unit_Standard_USD_jkFSuOOO40GksqLv6OFPVQ) | Source evidence |
|---|---|---|---|
| 2021 | Operating cash flow | -990296 |
|
| 2022 | Operating cash flow | -940718 |
|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value(Unit_Standard_USD_jkFSuOOO40GksqLv6OFPVQ) | Source evidence |
|---|---|---|---|
| 2021 | Free cash flow | Unavailable |
|
| 2022 | Free cash flow | Unavailable |
|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2021-12-31 | Liabilities / assets | Not reported | No source recorded |
| 2022-12-31 | Liabilities / assets | Not reported | No source recorded |
Current assets to current liabilities
Current assets divided by current liabilities.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2021-12-31 | Current assets / current liabilities | Not reported | No source recorded |
| 2022-12-31 | Current assets / current liabilities | Not reported | No source recorded |
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2021 2021-01-01 – 2021-12-31 | −Unit_Standard_USD_jkFSuOOO40GksqLv6OFPVQ 1.6 million Exact valueExact value: -1597755 Unit_Standard_USD_jkFSuOOO40GksqLv6OFPVQ 2021-01-01 – 2021-12-31: -1597755 Unit_Standard_USD_jkFSuOOO40GksqLv6OFPVQ Inspect Net Income Open source Share or citeThe citation records this snapshot. The page link may show a newer release later. | −Unit_Standard_USD_jkFSuOOO40GksqLv6OFPVQ 990,296 Exact valueExact value: -990296 Unit_Standard_USD_jkFSuOOO40GksqLv6OFPVQ 2021-01-01 – 2021-12-31: -990296 Unit_Standard_USD_jkFSuOOO40GksqLv6OFPVQ Inspect Operating Cash Flow Open source Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2022 2022-01-01 – 2022-12-31 | −Unit_Standard_USD_jkFSuOOO40GksqLv6OFPVQ 1.73 million Exact valueExact value: -1727455 Unit_Standard_USD_jkFSuOOO40GksqLv6OFPVQ 2022-01-01 – 2022-12-31: -1727455 Unit_Standard_USD_jkFSuOOO40GksqLv6OFPVQ Inspect Net Income Open source Share or citeThe citation records this snapshot. The page link may show a newer release later. | −Unit_Standard_USD_jkFSuOOO40GksqLv6OFPVQ 940,718 Exact valueExact value: -940718 Unit_Standard_USD_jkFSuOOO40GksqLv6OFPVQ 2022-01-01 – 2022-12-31: -940718 Unit_Standard_USD_jkFSuOOO40GksqLv6OFPVQ Inspect Operating Cash Flow Open source Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
120 filings · 3,805 latest values · 3,805 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0000707511, 707511, RGRX, edgar:707511, rgrx
Also known as ALPHA 1 BIOMEDICALS INC, ALPHA 1 BIOMEDICALS INC /DE/, REGENERX BIOPHARMACEUTICALS INC, REGENERX BIOPHARMACEUTICALS, INC., RegeneRx Biopharmaceuticals, Inc.